Jasper Therapeutics News

Jasper Therapeutics (JSPR.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -1.03 dollars, previous value of -1.60 dollars, expected value of -1.23 dollars.

Jasper Therapeutics (JSPR.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -1.03 dollars, previous value of -1.60 dollars, expected value of -1.23 dollars.

Zhitong Finance21:03

Jasper Therapeutics Q1 EPS $(1.03) Beats $(1.23) Estimate

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.23) by 16.26 percent. This is a 35.63 percent increase over losses of

Benzinga20:35

Jasper Therapeutics; Cash, Cash Equivalents as of March 31 Totaled $118.5M >JSPR

Jasper Therapeutics; Cash, Cash Equivalents as of March 31 Totaled $118.5M >JSPR

Dow Jones20:05

Jasper Therapeutics 1Q Loss/Shr $1.03 >JSPR

Jasper Therapeutics 1Q Loss/Shr $1.03 >JSPR

Dow Jones20:04

Press Release: Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jas

Dow Jones20:00

Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4

Jasper Therapeutics (JSPR) said Monday it is expanding the company's mast cell development portfolio and will evaluate briquilimab, a conditioning agent for patients undergoing stem cell transplant, i

MT Newswires00:59

Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET), Jasper Therapeutics (JSPR) and Lucid Diagnostics (LUCD)

TipRanksMay 13 23:50

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

PDF Version Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024Company to Host Key Opinion Leader Webinar on the Potential of B

Jasper TherapeuticsMay 13 12:00

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

PDF Version REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel anti

Jasper TherapeuticsMay 7 12:00

Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of Spirit Airlines, Inc. (NYSE:SAVE) fell sharply during Monday's session as the company reported a first-qu

BenzingaMay 7 01:05

Jasper Therapeutics Initiated at Buy by HC Wainwright & Co.

Jasper Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow JonesMay 6 18:50

Jasper Therapeutics (JSPR.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $65.00.

Jasper Therapeutics (JSPR.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $65.00.

Zhitong FinanceMay 6 18:40

HC Wainwright & Co. Initiates Coverage On Jasper Therapeutics With Buy Rating, Announces Price Target of $65

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Jasper Therapeutics with a Buy rating and announces Price Target of $65.

Analyst UpgradesMay 6 18:40

Buy Rating Affirmed: Jasper Therapeutics' Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment Market

TipRanksApr 25 10:55

Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) Market Cap Dropped US$88m Last Week; Individual Investors Who Hold 36% Were Hit as Were Institutions

Key Insights The considerable ownership by individual investors in Jasper Therapeutics indicates that they collectively have a greater say in management and business strategy A total of 12 investors

Simply Wall StApr 19 18:06

Jasper Therapeutics Initiated at Outperform by Evercore ISI Group

Jasper Therapeutics Initiated at Outperform by Evercore ISI Group

Dow JonesApr 3 19:44

Evercore ISI Group Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $65

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Jasper Therapeutics with a Outperform rating and announces Price Target of $65.

Analyst UpgradesApr 3 19:34

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

PDF Version REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel an

Jasper TherapeuticsApr 2 12:00

RBC Starts Jasper Therapeutics at Outperform, Cites Market Opportunity

Seeking AlphaMar 29 04:03

Jasper Therapeutics Initiated at Outperform by RBC Capital

Jasper Therapeutics Initiated at Outperform by RBC Capital

Dow JonesMar 28 16:46